Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...

AbbVie (NYSE: ABBV) today announced positive results from a new post-hoc analysis from the Measure Up 1 and Measure Up 2 Phase 3 studies. The analysis evaluated the efficacy of upadacitinib (15 mg or ...